{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T05:27:14Z","timestamp":1776317234656,"version":"3.50.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,8,12]],"date-time":"2020-08-12T00:00:00Z","timestamp":1597190400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ajog.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Obstetrics and Gynecology"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.ajog.2020.08.026","type":"journal-article","created":{"date-parts":[[2020,8,12]],"date-time":"2020-08-12T21:19:10Z","timestamp":1597267150000},"page":"200.e1-200.e9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Benefit and burden in the Dutch cytology-based vs high-risk human papillomavirus-based cervical cancer\u00a0screening program"],"prefix":"10.1016","volume":"224","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7397-8112","authenticated-orcid":false,"given":"Diede L.","family":"Loopik","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisanne M.","family":"Koenjer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albert G.","family":"Siebers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Willem J.G.","family":"Melchers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruud L.M.","family":"Bekkers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajog.2020.08.026_bib1","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1158\/1055-9965.EPI-04-0569","article-title":"Trends in cervical squamous cell carcinoma incidence in 13 European countries: changing risk and the effects of screening","volume":"14","author":"Bray","year":"2005","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.ajog.2020.08.026_bib2","first-page":"CD008054","article-title":"Human papillomavirus testing versus repeat cytology for triage of minor cytological cervical lesions","volume":"2013","author":"Arbyn","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ajog.2020.08.026_bib3","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1001\/jama.2018.10400","article-title":"Screening for cervical cancer with high-risk human papillomavirus testing: updated evidence report and systematic review for the US Preventive Services Task Force","volume":"320","author":"Melnikow","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.ajog.2020.08.026_bib4","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ygyno.2014.11.076","article-title":"Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test","volume":"136","author":"Wright","year":"2015","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ajog.2020.08.026_bib8","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1038\/sj.bjc.6603653","article-title":"High-risk HPV type-specific clearance rates in cervical screening","volume":"96","author":"Bulkmans","year":"2007","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ajog.2020.08.026_bib10","first-page":"CD012847","article-title":"Obstetric outcomes after conservative treatment for cervical intraepithelial lesions and early invasive disease","volume":"11","author":"Kyrgiou","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ajog.2020.08.026_bib11","first-page":"19","article-title":"Pathology databanking and biobanking in the Netherlands, a central role for PALGA, the nationwide histopathology and cytopathology data network and archive","volume":"29","author":"Casparie","year":"2007","journal-title":"Cell Oncol"},{"key":"10.1016\/j.ajog.2020.08.026_bib12","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1136\/jcp.2003.011841","article-title":"The Dutch CISOE-A framework for cytology reporting increases efficacy of screening upon standardisation since 1996","volume":"57","author":"Bulk","year":"2004","journal-title":"J\u00a0Clin Pathol"},{"key":"10.1016\/j.ajog.2020.08.026_bib13","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S1470-2045(09)70360-2","article-title":"Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial","volume":"11","author":"Ronco","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ajog.2020.08.026_bib14","doi-asserted-by":"crossref","first-page":"l240","DOI":"10.1136\/bmj.l240","article-title":"Primary cervical screening with high risk human papillomavirus testing: observational study","volume":"364","author":"Rebolj","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.ajog.2020.08.026_bib15","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/cyt.12652","article-title":"Implementation of HPV-based cervical cancer screening in an organised regional screening programme: 3 years of experience","volume":"30","author":"Veijalainen","year":"2019","journal-title":"Cytopathology"},{"key":"10.1016\/j.ajog.2020.08.026_bib16","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/ijc.28640","article-title":"Is HPV DNA testing specificity comparable to that of cytological testing in primary cervical cancer screening? Results of a meta-analysis of randomized controlled trials","volume":"135","author":"Pileggi","year":"2014","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ajog.2020.08.026_bib17","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S1470-2045(11)70296-0","article-title":"Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial","volume":"13","author":"Rijkaart","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ajog.2020.08.026_bib18","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/S0140-6736(13)62218-7","article-title":"Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials","volume":"383","author":"Ronco","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.ajog.2020.08.026_bib19","doi-asserted-by":"crossref","first-page":"c1804","DOI":"10.1136\/bmj.c1804","article-title":"Rate of cervical cancer, severe intraepithelial neoplasia, and adenocarcinoma in situ in primary HPV DNA screening with cytology triage: randomised study within organised screening programme","volume":"340","author":"Anttila","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.ajog.2020.08.026_bib20","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1186\/s12916-019-1460-0","article-title":"Introduction of primary screening using high-risk HPV DNA detection in the Dutch cervical cancer screening programme: a population-based cohort study","volume":"17","author":"Aitken","year":"2019","journal-title":"BMC Med"},{"key":"10.1016\/j.ajog.2020.08.026_bib21","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1002\/ijc.24010","article-title":"Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older","volume":"124","author":"Meijer","year":"2009","journal-title":"Int J Cancer"},{"issue":"Suppl10","key":"10.1016\/j.ajog.2020.08.026_bib22","doi-asserted-by":"crossref","first-page":"K29","DOI":"10.1016\/j.vaccine.2008.06.019","article-title":"Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries","volume":"26","author":"Cuzick","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.ajog.2020.08.026_bib23","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/aogs.13547","article-title":"Management and treatment of cervical intraepithelial neoplasia in the Netherlands after referral for colposcopy","volume":"98","author":"Aitken","year":"2019","journal-title":"Acta Obstet Gynecol Scand"},{"key":"10.1016\/j.ajog.2020.08.026_bib24","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1309\/AJCPZ5JY6FCVNMOT","article-title":"High-risk human papillomavirus testing in women with ASC-US cytology: results from the ATHENA HPV study","volume":"135","author":"Stoler","year":"2011","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.ajog.2020.08.026_bib25","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/dc.24029","article-title":"Does the \u2018equal management of equal risks\u2019 model cause overtreatment in patients with positive cervical cytology results for ASCUS\/non-HPV16\/18 oncogenic types?","volume":"47","author":"Karaca","year":"2019","journal-title":"Diagn Cytopathol"},{"key":"10.1016\/j.ajog.2020.08.026_bib26","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ygyno.2018.12.024","article-title":"Stratified risk of high-grade cervical disease using onclarity HPV extended genotyping in women, \u226525years of age, with NILM cytology","volume":"153","author":"Stoler","year":"2019","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ajog.2020.08.026_bib27","doi-asserted-by":"crossref","first-page":"356.e1","DOI":"10.1016\/j.ajog.2007.07.049","article-title":"Risk assessment to guide the prevention of cervical cancer","volume":"197","author":"Castle","year":"2007","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2020.08.026_bib28","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1080\/14737140.2016.1232166","article-title":"Triage of high-risk HPV positive women in cervical cancer screening","volume":"16","author":"Ebisch","year":"2016","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.ajog.2020.08.026_bib29","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/1471-0528.15957","article-title":"Triaging women with human papillomavirus infection and normal cytology or low-grade dyskaryosis: evidence from 10-year follow up of the ARTISTIC trial cohort","volume":"127","author":"Gilham","year":"2020","journal-title":"BJOG"},{"key":"10.1016\/j.ajog.2020.08.026_bib30","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1097\/AOG.0000000000000669","article-title":"Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance","volume":"125","author":"Huh","year":"2015","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajog.2020.08.026_bib31","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2018-001351","article-title":"Self-sampling for human papillomavirus (HPV) testing: a systematic review and meta-analysis","volume":"4","author":"Yeh","year":"2019","journal-title":"BMJ Glob Health"},{"key":"10.1016\/j.ajog.2020.08.026_bib32","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1016\/j.ejca.2011.11.022","article-title":"Offering self-sampling for human papillomavirus testing to non-attendees of the cervical screening programme: characteristics of the responders","volume":"48","author":"G\u00f6k","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ajog.2020.08.026_bib33","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1002\/ijc.22484","article-title":"Human papillomavirus testing on self-sampled cervicovaginal brushes: an effective alternative to protect nonresponders in cervical screening programs","volume":"120","author":"Bais","year":"2007","journal-title":"Int J Cancer"}],"container-title":["American Journal of Obstetrics and Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002937820308541?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002937820308541?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T11:31:09Z","timestamp":1757590269000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002937820308541"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S0002937820308541"],"URL":"https:\/\/doi.org\/10.1016\/j.ajog.2020.08.026","relation":{},"ISSN":["0002-9378"],"issn-type":[{"value":"0002-9378","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Benefit and burden in the Dutch cytology-based vs high-risk human papillomavirus-based cervical cancer\u00a0screening program","name":"articletitle","label":"Article Title"},{"value":"American Journal of Obstetrics and Gynecology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajog.2020.08.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}